Clinical Trial Update: A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Ga-68-NGUL and Lu-177-DGUL in metastatic castration-resistant prostate cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Ga-68-NGUL
• Lu-177-DGUL

Snippet

Sponsor: Cellbion Co., Ltd. | Conditions: Prostate Cancer, mCRPC | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING